Mylan Inc, founded in 1961 and headquartered in Canonsburg, Pennsylvania, is a global pharmaceutical company dedicated to developing and manufacturing generic and specialty medicines. With a diverse portfolio, Mylan offers a wide range of products including generic drugs, over-the-counter medications, and biosimilars across various therapeutic areas.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| MYL 2.13% 2025-05-23 EURMylan Inc | United States | 2025-05-23 | 2.125 | 2.81 |
| MYL 4.55% 2028-04-15 USDMylan Inc | United States | 2028-04-15 | 4.550 | 4.61 |
| MYL 4.55% 2028-04-15 USDMylan Inc | United States | 2028-04-15 | 4.550 | 4.42 |
| MYL 5.20% 2048-04-15 USDMylan Inc | United States | 2048-04-15 | 5.200 | 6.74 |
| MYL 5.20% 2048-04-15 USDMylan Inc | United States | 2048-04-15 | 5.200 | 6.43 |
| MYL 5.40% 2043-11-29 USDMylan Inc | United States | 2043-11-29 | 5.400 | 6.65 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Mylan has actively engaged in bond issuances since 2013, notably launching a debut offering of $5 billion in debt to finance its acquisition of the intravenous drug company, Mylan N.V. This marked a significant moment in their expansion strategy and allowed them to enhance liquidity and market presence. Currently, Mylan's corporate bonds yield approximately 4.5%, which is competitive within the pharmaceutical industry, making them an attractive option for investors seeking income in a stable sector.